- AstraZeneca to have clarity on future of vaccines by year-end
- Dobber: no decision taken yet on future of COVID-19 shot
- Dobber says vaccine is no distraction
LONDON, July 29 (Reuters) – AstraZeneca is exploring options for the future of its COVID-19 vaccine and expects greater clarity on the matter by the end of 2021, a senior executive said on Thursday, following a series of setbacks in its race to produce a shot for the world.
Executives emphasised it was too early to say what the decision on the vaccine’s future or the outcome of the review would be.
AstraZeneca (AZN.L) agreed to work with the University of Oxford on its COVID-19 shot last year despite having no prior vaccine experience, taking on the project with a pledge not to make a profit during the coronavirus pandemic.
While a $39 billion dollar deal to buy rare drug firm Alexion is much more integral to the company’s business strategy, the COVID-19 vaccine has quickly become the…